香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司關於為子公司提供擔保的進展公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 公司秘書 劉寧 中國，珠海 二零二六年二月四日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 本公司的職工董事為冉永梅女士；而本公司的獨立非執行董事為白華先生、羅會遠先生、 崔麗婕女士及王智瑤女士。 * 僅供識別 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2026-04 本公司及董事会 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2026-04 丽珠医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 丽珠医药集团股份有限公司（以下简称"公司"或"丽珠集团"）于 2025 年 3 月 26 日召开第十一届董事会第二十三次会议，于 2025 年 5 月 29 日召开 2024 年度股东大会、2025 年第一次 A 股类别股东会及 2025 年第一次 H 股类别股东 会，审议通过了《关于公司授信融资暨为下属附属公司提供融资担保的议案》， 同意公司为下属附属公司向国家开发银行等银行申请最高不超过人民币 141.50 亿元或等值外币的授信融资提供连带责任担保。具体内容详见公司 2025 年 3 月 27 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司授信融资暨为下属 附属公司提供融资担保的公告》（公告编号：2025-020）。 公司于 2024 年 9 月 27 日召开了第十一届董事会第十九次会议，于 2024 年 11 月 26 日 ...

Group 1 - The company is in a value realization phase, leveraging its technology platforms such as sustained-release microspheres, antibody drugs, and recombinant protein vaccines for product iteration and comprehensive layout in key areas like digestive tract, assisted reproduction, and mental health [1] - Multiple drugs are at various research stages, with the monoclonal antibody Lakanqita already submitted for market approval for moderate to severe psoriasis and included in the priority review process, showing significant clinical value [1] - The company plans to acquire 64.81% of Vietnam's IMP Company by May 2025, which is expected to enhance its global commercialization strategy [1] Group 2 - Revenue forecasts for the company from 2025 to 2027 are projected at 11.977 billion, 12.028 billion, and 12.996 billion yuan, with year-on-year growth rates of 1.4%, 0.4%, and 8.1% respectively [2] - Net profit attributable to shareholders is expected to be 2.173 billion, 2.227 billion, and 2.528 billion yuan for the same period, with growth rates of 5.4%, 2.5%, and 13.5% respectively [2] - The company is rated as "overweight" with corresponding PE ratios of 14.3, 13.9, and 12.3 times based on the closing price on January 30 [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麗珠醫藥集團股份有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 299,807,117 | RMB | | 1 RMB | | 299,807,117 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 299,807,117 | RMB | | 1 RMB | | 299,807,117 | | 2. 股份分類 | 普通股 | 股份類別 | A | | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 麗珠醫藥集團股份有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 299,807,117 | RMB | | 1 RMB | | 299,807,117 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 299,807,117 | RMB | | 1 RMB | | 299,807,117 | | 2. 股份分類 | 普通股 | 股份類別 | A | | ...

Core Viewpoint - The company adopts a "dual-track" strategy for its international expansion, focusing on both licensing out innovative products to mature markets and direct exports to emerging markets to establish a global sales network [1] Group 1: Licensing Strategy - The company is currently focusing on overseas rights cooperation for its core product, Lecanemab, in the self-immune field, which has attracted attention from multiple overseas pharmaceutical companies due to its clinical efficacy and low dosing frequency [1] - The partnership with XinKang allows for shared overseas rights, enhancing the product's market potential [1] Group 2: Export Strategy - The company has systematically laid out its export strategy since 2022, prioritizing Southeast Asia and South America as key emerging markets [1] - The decision is based on three core considerations: 1. Regional driving effect, using Vietnam and Brazil as pivotal points to accelerate market expansion due to their robust drug regulatory systems [1] 2. Registration synergy, as Southeast Asian countries generally recognize or can reference Chinese clinical research data, speeding up the approval process [1] 3. Market growth potential, with Vietnam's pharmaceutical market maintaining double-digit growth and Brazil being the largest pharmaceutical market in Latin America [1] Group 3: Implementation Measures - In Southeast Asia, the company is building a localized production and sales platform through the acquisition of the Vietnamese listed company IMP [1] - In South America, the focus is on Brazil, actively promoting product registration and channel development, leveraging its efficient review process to accelerate product entry [1] - The company expects that through 2-3 years of strategic layout and cultivation, its overseas formulation business will gradually scale up and contribute positively to financial performance in the future [1]

Core Viewpoint - Lijun Group (000513) has stated that Lijun Biotech is the only biopharmaceutical platform shared with Health Yuan (600380), focusing on three main business segments: autoimmune, reproductive, and vaccine fields [1]. Group 1 - Lijun Biotech is a collaborative platform between Lijun Group and Health Yuan [1] - The company operates in three primary business areas: autoimmune, reproductive, and vaccine sectors [1]

Core Viewpoint - Lijun Group's research indicates significant advancements in its biopharmaceutical platform, focusing on autoimmune, reproductive, and vaccine sectors, with key products nearing approval and promising clinical results [1][4][5] Group 1: Autoimmune Sector - Lijun Biopharmaceutical's core product, Lakanqita monoclonal antibody, shows a PASI100 response rate of 49.5% in severe psoriasis, outperforming the control group at 40.2%, and is expected to receive approval by the end of this year [1][6][7] - The company has completed Phase III clinical trials for ankylosing spondylitis, with approval anticipated next year, and significant sales growth for another product, tocilizumab, is expected in 2025 [1][4] Group 2: Reproductive Sector - The recombinant human follicle-stimulating hormone injection is expected to be approved within this year, reinforcing the company's leading position in the assisted reproductive field [1][4] Group 3: Vaccine Sector - The quadrivalent influenza recombinant protein vaccine, the first of its kind with an adjuvant, has completed Phase I safety trials and is expected to enter Phase II clinical trials in March [5] Group 4: Overseas Expansion Strategy - The company adopts a "dual-track" strategy for international expansion, focusing on licensing its innovative pipeline to mature markets and exporting formulations to emerging markets [2][9] - In Southeast Asia, the company is building a localized platform through the acquisition of IMP in Vietnam, while in South America, it is prioritizing registration and channel development in Brazil [9] Group 5: Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category in China, showing comparable efficacy to enoxaparin with a lower bleeding risk, and is preparing for Phase III trials [3][10] Group 6: GnRH Pipeline - The GnRH pipeline covers all indications and various formulations, with key products like the three-month formulation of leuprolide expected to be approved this year [11][12] Group 7: Chemical Preparation Sector - The chemical preparation sector generated 47.2 billion yuan in revenue from January to September 2025, accounting for 51.8% of the company's total revenue, serving as a core revenue support [13][14] - Future growth will be driven by product upgrades, innovative product launches, and deepening market penetration in core therapeutic areas [14][15][16]

Core Viewpoint - The company, Lizhu Group, has announced that its core product, Lakanqita monoclonal antibody, has outperformed Secukinumab in the primary endpoint of a Phase III head-to-head clinical trial for moderate to severe psoriasis, with a PASI 100 response rate at week 12 [1] Group 1 - The product is the first IL-17A/F dual-target inhibitor in China, offering advantages such as less frequent dosing, convenient administration, and excellent safety profile [1] - The company has submitted for market approval and has been included in the CDE's priority review, with the earliest expected approval by the end of 2026 [1] - Cost competitive barriers have been established through the localization of raw materials and process optimization, laying a foundation for future market access and commercialization [1]

Business Overview - Lizhu Biopharmaceuticals operates three main business segments: autoimmune, reproductive, and vaccine fields [2][3] - The core product in the autoimmune field, Lakanqita monoclonal antibody, has shown superior efficacy in clinical trials compared to competitors [4][5] Autoimmune Field - Lakanqita monoclonal antibody targets IL-17A/F dual sites, with a PASI100 response rate of 49.5% in clinical trials, outperforming the control group at 40.2% [4] - The product is expected to receive approval by the end of 2026, with significant market potential due to its unique characteristics [5] Reproductive Field - The recombinant human follicle-stimulating hormone (r-FSH) injection is anticipated to be approved within the year, reinforcing the company's leadership in assisted reproduction [3] Vaccine Field - The quadrivalent recombinant protein influenza vaccine is the first of its kind with an adjuvant, having completed Phase I trials and expected to enter Phase II in March [3] International Expansion Strategy - The company adopts a dual-track strategy for international expansion, focusing on licensing out innovative pipelines and direct exports to emerging markets [5][6] - Key markets include Southeast Asia and South America, with Vietnam and Brazil as strategic hubs for regulatory advantages and market growth [6] Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category, aimed at preventing venous thromboembolism (VTE) post-orthopedic surgeries [7] - The product has shown comparable efficacy to standard therapies and is preparing for Phase III trials [8] GnRH Pipeline - The GnRH pipeline covers all related indications and various formulations, making it the most comprehensive in China [9] - Key products include leuprolide with multiple formulations expected to launch soon, enhancing market presence [9] Chemical Preparation Segment - The chemical preparation segment generated revenue of 4.72 billion CNY, accounting for 51.8% of the company's total revenue in the first nine months of 2025 [10][11] - Growth drivers include product upgrades, innovation, and a focus on core therapeutic areas [11][12]